Neoantigens arising from somatic mutations in tumor cells are presented as peptides by HLA-class I molecules on tumor cells and are recognized by CD8+ (cytotoxic) T cells, which trigger killing of tumor cells. The gene discussed is CD8A; the disease is neoplasm.